Aviragen Therapeutics, Inc., formerly Biota Pharmaceuticals, Inc., is focused on the discovery and development of direct-acting antivirals to treat infections that affect patients globally. The Company has three product candidates in clinical development that address viral infections that have limited therapeutic options. Its products include vapendavir, an oral treatment for human rhinovirus (HRV) upper respiratory infections in moderate-to-severe asthmatics in Phase IIb SPIRITUS trial; BTA585, an oral fusion (F) protein inhibitor in Phase II development for the treatment and prevention of respiratory syncytial virus (RSV) infections, and BTA074, a topical antiviral treatment in Phase II development for condyloma caused by human papillomavirus Types 6 and 11. It has preclinical RSV non-fusion inhibitor program. It has focused its research and drug development capabilities on discovering and developing small molecule compounds that can prevent or treat infectious diseases.
Industry, Sector and Symbol:
- Trailing P/E Ratio:
- P/E Growth:
- Net Margins: -89.80%
- Return on Equity: -67.62%
- Return on Assets: -34.20%
Frequently Asked Questions for Aviragen Therapeutics (NASDAQ:NABI)
What is Aviragen Therapeutics' stock symbol?
Aviragen Therapeutics trades on the NASDAQ under the ticker symbol "NABI."
Who are some of Aviragen Therapeutics' key competitors?
Some companies that are related to Aviragen Therapeutics include Amgen (AMGN), Celgene Corporation (CELG), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals Incorporated (VRTX), TESARO (TSRO), Exelixis (EXEL), Bioverativ (BIVV), Kite Pharma (KITE), bluebird bio (BLUE), Clovis Oncology (CLVS), Neurocrine Biosciences (NBIX), Intercept Pharmaceuticals (ICPT), Juno Therapeutics (JUNO), China Biologic Products (CBPO), Agios Pharmaceuticals (AGIO), Ultragenyx Pharmaceutical (RARE) and GW Pharmaceuticals PLC (GWPH).
Who are Aviragen Therapeutics' key executives?
Aviragen Therapeutics' management team includes the folowing people:
- Mark P. Colonnese, Chief Financial Officer, Executive Vice President
- Russell H. Plumb, Executive Chairman of the Board
- Joseph M. Patti Ph.D., President, Chief Executive Officer, Director
- Armando Anido, Independent Director
- Geoffrey F. Cox Ph.D., Independent Director
- Michael R. Dougherty, Independent Director
- Michael W. Dunne M.D., Independent Director
- John P. Richard, Independent Director
How do I buy Aviragen Therapeutics stock?
MarketBeat Community Rating for Aviragen Therapeutics (NASDAQ NABI)MarketBeat's community ratings are surveys of what our community members think about Aviragen Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Shares of Aviragen Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
Consensus Ratings for Aviragen Therapeutics (NASDAQ:NABI) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|
Analysts' Ratings History for Aviragen Therapeutics (NASDAQ:NABI)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Aviragen Therapeutics (NASDAQ:NABI)Earnings History by Quarter for Aviragen Therapeutics (NASDAQ NABI)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for Aviragen Therapeutics (NASDAQ:NABI)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Aviragen Therapeutics (NASDAQ:NABI)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Aviragen Therapeutics (NASDAQ:NABI)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Aviragen Therapeutics (NASDAQ:NABI)
Latest Headlines for Aviragen Therapeutics (NASDAQ:NABI)
No headlines for this company have been tracked by MarketBeat.com
Aviragen Therapeutics (NABI) Chart for Tuesday, June, 27, 2017